While GlaxoSmithKline and Roche have taken steps to make clinical trial data publicly available, some within the industry remain resistant to greater transparency. And a leaked memo shows they are devising strategies to counter European proposals for a public database.
Sent to deal with the developing case personally, emerging markets chief Abbas Hussain met with ministry officials--and reportedly apologized to them. Afterward, Hussain admitted that top execs had probably breached Chinese law. And then, adding a sweetener to his mea culpa, Hussain promised changes that would cut the prices of his company's drugs in China.
Police visited AstraZeneca's operations in Huangpu Friday and took a sales rep away for questioning, Reuters reports. The company said the visit was part of a "local police matter" and tried to distance itself from the fast-moving GlaxoSmithKline bribery scandal.
Given that China is preventing a top GlaxoSmithKline exec from leaving the country as it investigates alleged bribery in the country, it seems risky to send more of his colleagues into the fray. But that is what the British drugmaker is doing, even as the probe widens to other companies.
In the midst of investigating GSK for bribery, Chinese officials confined GSK finance chief Steve Nechelput to the country at the end of June, Reuters reports. His boss, China general manager Mark Reilly, got out on June 27, Bloomberg reports, citing Chinese officials.
Could China's very public bribery probe of GlaxoSmithKline, its review of pharmaceutical pricing and a new crackdown on quality be a master scheme to get drugmakers to cut prices so that China can deliver on its promise of affordable healthcare for its citizens?
The news about GlaxoSmithKline's activities in China is getting more dramatic by the day. But now, the British drugmaker can take comfort in the fact that it's not alone.
A new paper has validated the Centers for Disease Control and Prevention's 2011 recommendation that males receive the HPV vaccine, particularly men who have sex with men, who are a higher risk group.
Chinese law enforcement officials investigating GlaxoSmithKline for allegedly bribing docs to get business say that in the process, they have uncovered information on the same kinds of tactics being used by other foreign drugmakers. They have not said if they will follow up on those leads.
GlaxoSmithKline faced a barrage of headlines around the world after Chinese police officials made a series of salacious allegations about widespread corruption while raising questions about the absence of GlaxoSmithKline's China operations, Mark Reilly, who left the country on June 27 and has not returned.